( )  

Aldevron

Designed for you.

Sidebar
Menu

Tailor-made antibodies to suit every client's needs

Aldevron's GENOVAC Antibody Technology supports all project types from reagent antibodies to diagnostic and therapeutic applications with high success rates. Based on many years of experience, our technology has been developed to cater for all protein targets where other methods have failed. Our custom antibodies have been validated in over 130 publications and patents for more than 500 clients worldwide.

Learn more about our genetic, protein, and peptide immunization strategies. Please fill out the Aldevron Antibody Services Questionnaire today to see how we can best customize our services for you.

Additional services include antibody processing, production, labeling, characterization and sequencing. Contact Aldevron if you are interested in any additional antibody related services.

Ready-to-ship antibodies

Aldevron applies its unique antibody technology to develop its own catalog of highly specific monoclonal antibodies. Visit our ready-to-ship antibodies for more information.
As of July 1, 2011 GENOVAC has officially changed it's name to Aldevron Freiburg. The core team and technologies will remain intact. Representing the antibody arm of Aldevron, Aldevron Freiburg will continue being a world leader in genetic immunization utilizing GENOVAC Antibody Technology™.

GENOVAC product and services have been migrated to the Aldevron website and are available at
aldevron.com/genovac. If you have any questions, please do not hesitate to contact Aldevron.
GENOVAC was first registered as a limited company (GmbH) in December 1999 in Freiburg im Breisgau, South West Germany, by Fritz Grunert, John Thompson and Wolfgang Zimmermann. The three founders were group leaders at the Institute of Immunobiology, University of Freiburg and have a longstanding experience in tumor biology and the development of antibodies against carcinoembryonic antigen (CEA) and related molecules. During this time, they built up contacts to top laboratories working in the field of tumor biology worldwide.

On January 1, 2004 GENOVAC became a part of Aldevron LLC, USA. Both companies have specialized in the area of genetic immunization to develop antibodies. The combined expertise and clientele continue to strengthen Aldevron as a world-leader in antibody technology.
Aldevron Freiburg is based in Freiburg, Germany, which is located in the middle of one of the largest biotechnology centres (BioValley) at a three nation border in the heart of Europe. This region includes Basel, Freiburg and Strasbourg, which apart from a concentration of large pharmaceutical companies (e.g., Novartis and Roche) all have well-known universities and research institutes (e.g., Friedrich Miescher Institute, Basel and Max-Planck Institute of Immunology in Freiburg)

Continue to www.aldevron.com/genovac

Du SX, et al (2009): Effect of trimerization motifs on quaternary structure, antigenicity, and immunogenicity of a noncleavable HIV-1 gp140 envelope glycoprotein. Virology, 395(1):33-44.
Hooper JW, et al (2008): Immune serum produced by DNA vaccination protects hamsters against lethal respiratory challenge with Andes virus. FJ Virol., 82(3):1332-8.
Elagoz A, et al (2004): A truncated form of CKbeta8-1 is a potent agonist for human formyl peptide-receptor-like 1 receptor. Br J Pharmacol., 141(1):37-46.
Project Application Aldevron's Advantage
Target extracellular domains of six GPCRs: FPRL1, RDC1, CXCR7, LGR4, LGR5 and LGR6 Therapeutics and diagnostics Allows generation of antagonistic antibodies against GPCRs with an unprecedented success rate
Block HCV entry into human liver cells Potential HCV therapy Allows generation of blocking antibodies:
  • for all 6 HCV genotypes and all HCV quasi-species from at least 2 HCV patients
  • which reveal no measurable toxicity on primary human liver cells
Differentiate two highly homologous cell surface receptors (Claudin 6 and 9) Potential HCV therapy Allows generation of antibodies specific of two highly conserved tetraspanin molecules (3 amino acid differences between the extracellular domains)
Generate antibodies against bacterial toxins (Clostridium botulinum neurotoxin light chain serotypes A and B) Potential therapy Allows generation of antibodies against toxic proteins
Differentiate epitopes with low immunogenicity Target validation Allows generation of antibodies against immunorecessive epitopes of CEACAM1
REAGENTS THAT BIND CCX-CKR2
Publication/Patent number:WO2006116319
Publication date:2006-11-02
Inventor:Howard Maureen (US); Schall Thomas (US)
Applicant:Chemocentryx Inc (US); Howard Maureen (US); Schall Thomas (US)
Antigen:neutralizing monoclonal antibody against CCX-CKR2 / RDC1
  
ANTIBODIES THAT BIND CXCR7 EPITOPES
Publication/Patent number: US20090022717
Publication date: 2009-01-22
Inventor: Premack Brett (US); Miao Zhenhua (US); Penfold Mark (US)
Applicant: ChemoCentryx, Inc. (US)
Antigen: neutralizing monoclonal antibody against CXCR7
  
A METHOD FOR IDENTIFYING, EXPANDING, AND REMOVING ADULT STEM CELLS AND CANCER STEM CELLS
Publication/Patent number: WO2009022907
Publication date: 2009-02-19
Inventor: Clevers Johannes Carolus [NL]; Barker Nicholas [NL]; Haegebarth Andrea [DE]; Van De Wetering Marcus Lambertus [NL]
Applicant: Hubrecht Inst [NL]; Konink NL Akademie Van Wetensc [NL]; Clevers Johannes Carolus [NL]; Barker Nicholas [NL]; Haegebarth Andrea [DE]; Van De Wetering Marcus Lambertus [NL]
Antigen: LGR5 (GPR49) and LGR6
  
ANTIBODIES RECOGNIZING ENDOGENOUS HUMAN LGR5 AND/OR LGR6
Publication/Patent number: WO2010016766
Publication date: 2010-02-11
Inventor: CLEVERS JOHANNES CAROLUS [NL]; BARKER NICHOLAS [NL]; HAEGEBARTH ANDREA [DE]; VAN DE WETERING MARCUS LAMBERTUS [NL]
Applicant: KONINK NL AKADEMIE VAN WETENSC [NL]; KONINK NL AKADEMIE VAN WETENSC [NL]; HUBRECHT LAB [NL]; CLEVERS JOHANNES CAROLUS [NL]; BARKER NICHOLAS [NL]; HAEGEBARTH ANDREA [DE]; VAN DE WETERING MARCUS LAMBERT [NL]
Antigen: LGR5 and LGR6
  
MONOCLONAL ANTI-CLAUDIN 1 ANTIBODIES FOR THE INHIBITION OF HEPATITIS C VIRUS INFECTION
Publication/Patent number: WO2010034812
Publication date: 2010-04-01
Inventor: BAUMERT THOMAS [FR]; SCHUSTER CATHERINE [FR]; THOMPSON JOHN [DE]; GRUNERT FRITZ [DE]
Applicant: INST NAT SANTE RECH MED [FR]; GENOVAC [DE]; UNIV STRASBOURG [FR]; BAUMERT THOMAS [FR]; SCHUSTER CATHERINE [FR]; THOMPSON JOHN [DE]; GRUNERT FRITZ [DE]
Antigen: Claudin 1
  
CLDN6_small

Genetic immunization allowed generation of mAbs that differentiate
two highly conserved tetraspanin molecules
(Claudin 6 and Claudin 9).
Study completed in collaboration with INSERM (Strasbourg, France)

facscan2